Skip to main content

Market Overview

TherapeuticsMD: Q3 Earnings Insights

Share:

 

Shares of TherapeuticsMD (NASDAQ:TXMD) moved higher by 2.5% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share increased 7.69% year over year to ($0.12), which beat the estimate of ($0.14).

Revenue of $19,342,000 declined by 18.46% year over year, which beat the estimate of $15,330,000.

Outlook

TherapeuticsMD hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 09, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/2wxgyncb

Price Action

52-week high: $2.96

52-week low: $0.85

Price action over last quarter: down 25.15%

Company Description

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

 

Related Articles (TXMD)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com